Pete Wehrly previously served in multiple senior roles at Covidien plc (“Covidien”), including Group President of Developed Markets and Group President of Respiratory & Monitoring Solutions and Vascular Therapies, from 2009 until 2015, during which Covidien was a public company listed on the New York Stock Exchange. Prior to joining Covidien, Pete served as President and Chief Executive Officer at Medingo Ltd. an Israel based company from 2008-2009. From 2000 to 2008 he held senior executive-level roles at Medtronic Spinal and Biologics in Memphis, Tennessee, where he oversaw the global market expansion of that company’s core spinal fusion therapies, minimal access technologies, motion-sparing devices and biologic technologies. Prior to that, he spent 17 years at DePuy, a division of Johnson & Johnson, and served as DePuy’s Sports Medicine Division President from 1997 to 2000. Throughout his career at various companies, Pete headed regional strategies to gain regulatory approval and reimbursement for new technologies in Europe, Japan, Australia, New Zealand, the United States and Canada. In addition, since 2012, he has been a director of Non Linear Technologies Ltd. Pete holds a Bachelor of Science in Management from Ball State University in Muncie, Indiana and has been a member of a number of community boards.